Opportunity Information: Apply for RFA CA 18 029
The Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required) opportunity (RFA-CA-18-029) is a National Institutes of Health, National Cancer Institute cooperative agreement designed to build and support a set of clinical trial sites that can rapidly run early-stage cancer prevention trials. The central idea is to create consortia that are ready to test NCI-sponsored preventive agents in a disciplined, efficient way, with a strong emphasis on understanding what those agents do biologically in people and how those biological effects connect to clinically meaningful endpoints. Because the mechanism is a cooperative agreement (UG1), awardees should expect substantial programmatic involvement from NIH/NCI staff compared to a standard grant, with coordinated priorities, shared procedures, and network expectations.
The scientific purpose focuses on moving potential cancer preventive agents forward by generating high-quality early clinical evidence. Supported studies are explicitly early phase clinical trials, including phase 0 microdosing trials (to look at pharmacokinetics or target engagement at very low doses), phase I dose-finding trials (to establish dosing, safety, and tolerability in the prevention setting), and phase II trials aimed at preliminary efficacy signals (often using intermediate endpoints, biomarkers, or defined risk cohorts rather than cancer incidence alone). The agents of interest are NCI-sponsored and may span multiple classes, particularly those aimed at molecular targets or biological processes known to play important roles in carcinogenesis.
A major emphasis of the program is translational measurement: trials are not only meant to ask whether an intervention is safe or promising, but also to explain how it is working in humans. Applicants and funded sites are expected to measure effects on the intended molecular targets and on broader biological events tied to cancer development. The announcement highlights examples such as changes in cell proliferation, apoptosis, growth factor and oncogene expression patterns, and immune response. Just as important is linking those changes to clinical endpoints that matter in prevention research, such as validated or emerging biomarkers, tissue-based changes, lesion modulation in relevant settings, or other clinically relevant correlates that can help determine whether an agent should advance to later-stage prevention studies.
Beyond evaluating specific agents, CP-CTNet is also meant to deepen scientific understanding of prevention mechanisms and strengthen the marker-development pipeline. Sites are expected to help generate insights into why a preventive agent succeeds or fails, identify determinants of response, and continue developing novel markers that could be used in future trials to select participants, monitor biologic activity, predict benefit, or refine dosing strategies. In practice, this makes the program well-suited to institutions with strong capabilities in clinical trial operations plus integrated laboratory, pathology, biostatistics, and biomarker assay expertise.
In terms of eligibility, the opportunity is open to a broad range of U.S.-based organizations, including state governments; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding higher education where specified); and for-profit organizations other than small businesses. The announcement also explicitly notes inclusion of several institution types often highlighted for federal eligibility outreach, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and U.S. territories or possessions. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible; however, foreign components as defined in the NIH Grants Policy Statement are allowed, meaning a U.S. applicant can include certain international elements under NIH rules when scientifically justified.
Key administrative details included in the source information are that the opportunity is categorized as discretionary funding and uses the cooperative agreement funding instrument. It falls under education and health activity categories and is associated with CFDA numbers 93.393 and 93.399. The posting indicates an award ceiling of $625,000 (as listed in the opportunity data). The original closing date was November 15, 2018, and the creation date was September 14, 2018, indicating this specific announcement is historical, though it reflects the structure and goals that can reappear in related NCI prevention network initiatives.
Overall, this funding opportunity is aimed at establishing or supporting high-performing CP-CTNet trial sites that can run coordinated, early-phase cancer prevention clinical trials of NCI-sponsored agents, generate rigorous pharmacologic and biologic readouts, and produce actionable biomarker and mechanism insights that reduce uncertainty and speed decision-making about which prevention strategies deserve larger, later-stage testing.Apply for RFA CA 18 029
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
- This funding opportunity was created on 2018-09-14.
- Applicants must submit their applications by 2018-11-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $625,000.00 in funding.
- Eligible applicants include: State governments, Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the CP-CTNet Sites (UG1 Clinical Trial Required) funding opportunity?
This opportunity (RFA-CA-18-029) is a National Institutes of Health (NIH), National Cancer Institute (NCI) cooperative agreement (UG1) intended to build and support a set of clinical trial sites that can rapidly conduct early-stage cancer prevention clinical trials of NCI-sponsored preventive agents.
What is the overall goal of CP-CTNet?
The goal is to establish consortia of sites that are operationally ready to run coordinated, disciplined, efficient early-phase cancer prevention trials, with a strong focus on understanding what preventive agents do biologically in humans and how those effects relate to clinically meaningful prevention endpoints.
What does "UG1 cooperative agreement" mean for awardees?
Because the mechanism is a cooperative agreement (UG1), awardees should expect substantial programmatic involvement from NIH/NCI staff compared to a standard grant. This includes coordinated priorities, shared procedures, and network expectations across participating sites.
What types of clinical trials are supported under this announcement?
Supported studies are explicitly early-phase cancer prevention clinical trials, including:
- Phase 0 microdosing trials (e.g., to assess pharmacokinetics or target engagement at very low doses)
- Phase I dose-finding trials (to establish dosing, safety, and tolerability in a prevention setting)
- Phase II trials (to look for preliminary efficacy signals, often using intermediate endpoints, biomarkers, or defined risk cohorts rather than cancer incidence alone)
Is this opportunity focused on cancer treatment trials or prevention trials?
It is focused on cancer prevention trials, specifically early-stage trials that evaluate preventive agents and generate high-quality clinical and translational evidence relevant to prevention research.
What kinds of agents are expected to be tested?
The agents of interest are NCI-sponsored preventive agents. They may span multiple classes, particularly agents aimed at molecular targets or biological processes known to play important roles in carcinogenesis.
What is meant by a strong emphasis on translational measurement?
Trials are expected to do more than assess safety or early promise. Sites are expected to measure effects on intended molecular targets and broader biological events tied to cancer development, and then relate those biological effects to clinically relevant prevention endpoints.
What examples of biological effects or pathways are highlighted as important to measure?
The opportunity highlights examples such as changes in cell proliferation, apoptosis, growth factor and oncogene expression patterns, and immune response, as part of understanding how preventive agents act in humans.
What types of endpoints are considered clinically meaningful in this early prevention trial setting?
Rather than relying on cancer incidence alone, the announcement emphasizes endpoints relevant to prevention research, including validated or emerging biomarkers, tissue-based changes, lesion modulation in relevant settings, and other clinically relevant correlates that can inform whether an agent should advance to later-stage prevention studies.
Beyond testing agents, what additional scientific contributions are CP-CTNet sites expected to make?
Sites are expected to help deepen scientific understanding of prevention mechanisms and strengthen the marker-development pipeline. This includes generating insights into why an agent succeeds or fails, identifying determinants of response, and developing novel markers to support future trial design and decision-making.
What kinds of institutional capabilities are a good fit for this program?
The program is well-suited to institutions with strong clinical trial operations and integrated expertise in laboratory science, pathology, biostatistics, and biomarker assay development, since trials are expected to produce rigorous pharmacologic and biologic readouts.
Who is eligible to apply?
The opportunity is open to a broad range of U.S.-based organizations, including:
- State governments
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofit organizations (501(c)(3) and non-501(c)(3), excluding higher education where specified)
- For-profit organizations other than small businesses
Are specific institution types explicitly noted as included in eligibility outreach?
Yes. The announcement explicitly notes inclusion of institution types often highlighted for federal eligibility outreach, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and U.S. territories or possessions.
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible to apply.
Can a U.S. applicant include non-U.S. components?
No. Non-U.S. components of U.S. organizations are not eligible under this announcement.
Are any international elements allowed at all?
Yes. Foreign components (as defined in the NIH Grants Policy Statement) are allowed, meaning a U.S. applicant may include certain international elements under NIH rules when scientifically justified.
What federal agency and institute sponsor this opportunity?
The opportunity is sponsored by the National Institutes of Health (NIH), specifically the National Cancer Institute (NCI).
How is this opportunity categorized in the source information?
It is categorized as discretionary funding and uses the cooperative agreement funding instrument.
What activity categories are associated with this opportunity?
The source information associates the opportunity with education and health activity categories.
What CFDA numbers are associated with this announcement?
The associated CFDA numbers listed are 93.393 and 93.399.
What is the award ceiling listed for this opportunity?
The posting indicates an award ceiling of $625,000.
What were the key dates for this specific announcement?
The creation date was September 14, 2018, and the original closing date was November 15, 2018.
Is this announcement current or historical?
Based on the dates provided (2018), this specific announcement is historical. However, it reflects a structure and set of goals that can reappear in related NCI prevention network initiatives.
What is the main value a funded CP-CTNet site is expected to deliver?
A funded site is expected to conduct coordinated, early-phase cancer prevention trials of NCI-sponsored agents and to generate rigorous pharmacologic, biologic, biomarker, and mechanism insights that reduce uncertainty and speed decision-making about whether prevention strategies should advance to larger, later-stage testing.
Browse more opportunities from the same category: Education, Health
Next opportunity: Innovative Approaches for Improving Environmental Health Literacy (R41/R42 Clinical Trial Not Allowed)
Previous opportunity: International Bioethics Research Training Program (D43 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 18 029
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 18 029) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Coordinating Center (DMACC) (U24 Clinical Trials Required) Apply for RFA CA 18 030 Funding Number: RFA CA 18 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 19 002 Funding Number: RFA CA 19 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R41/R42 - Clinical Trial Optional) Apply for RFA DA 19 015 Funding Number: RFA DA 19 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R43/R44 - Clinical Trial Optional) Apply for RFA DA 19 014 Funding Number: RFA DA 19 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Responding to Opioid Use Disorders (OUD) in Tribal Communities in the Context of SAMHSA and CDC Funding (R61/R33 - Clinical Trials Optional) Apply for RFA DA 19 013 Funding Number: RFA DA 19 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional) Apply for PA 18 932 Funding Number: PA 18 932 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network (Admin Suppl - Clinical Trial Not Allowed) Apply for PAR 18 931 Funding Number: PAR 18 931 Agency: National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) Apply for PAR 18 947 Funding Number: PAR 18 947 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional) Apply for PA 18 943 Funding Number: PA 18 943 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional) Apply for PA 18 944 Funding Number: PA 18 944 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional) Apply for PA 18 946 Funding Number: PA 18 946 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional) Apply for PA 18 945 Funding Number: PA 18 945 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21 Clinical Trial Not Allowed) Apply for PAR 19 019 Funding Number: PAR 19 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R01 Clinical Trial Not Allowed) Apply for PAR 19 018 Funding Number: PAR 19 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing Caregiver Symptoms through Technological Tools (R01 Clinical Trial Optional) Apply for PA 19 023 Funding Number: PA 19 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing Caregiver Symptoms through Technological Tools (R21 Clinical Trial Optional) Apply for PA 19 024 Funding Number: PA 19 024 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed) Apply for PA 19 034 Funding Number: PA 19 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed) Apply for PA 19 033 Funding Number: PA 19 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Promoting Research on Music and Health: Fundamentals and Applications (R01 Clinical Trials Optional) Apply for RFA NS 19 008 Funding Number: RFA NS 19 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional) Apply for PAR 19 045 Funding Number: PAR 19 045 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 18 029", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.